Redefining the term Incubation Period using large scale digital data
Infectious diseases pose one of the greatest risks for a global catastrophe. Just like controlling the spread of wildfires, an early detection of infectious diseases is instrumental to containing outbreaks. Nearly all infections s...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
M-Eco
The Medical Ecosystem Personalized Event based Surveillanc...
3M€
Cerrado
ISSC
An integrated surveillance system for infectious disease in...
4M€
Cerrado
CONTAGIO
Cohort Network To be Activated Globally In Outbreaks
2M€
Cerrado
CTQ2014-59808-R
METODOLOGIA PARA EL RECONOCIMIENTO Y BIODETECCION DE NUEVOS...
138K€
Cerrado
INFECT-ERA
Coordination of European funding for infectious diseases res...
2M€
Cerrado
TB-RECONNECT
Reconnecting transmission to global tuberculosis control by...
3M€
Cerrado
Información proyecto DCUBATION
Duración del proyecto: 57 meses
Fecha Inicio: 2021-01-13
Fecha Fin: 2025-10-31
Líder del proyecto
TEL AVIV UNIVERSITY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Infectious diseases pose one of the greatest risks for a global catastrophe. Just like controlling the spread of wildfires, an early detection of infectious diseases is instrumental to containing outbreaks. Nearly all infections start silently, and gradually progress until clinical symptoms appear. In this silent period, the incubation period (IP), pathogens inhibit major pathways of the innate immune system, allowing an extended period of unhindered replication. The rate of replication, as well as the type and length of suppressed symptoms vary considerably between pathogens, creating a unique signature for each pathogen. Thus, improved understanding of the IP is pivotal for early detection, prevention and control of infectious diseases. Previous studies estimating IPs have used aggregated retrospective data, and are subject to the biases of patient self-reporting. I hypothesise that the actual onset of clinical symptoms occurs earlier than previously known, can be identified more accurately, and can be used in real-time for patient empowerment. Focusing on respiratory infections, my methodological approach includes: 1) real-time evaluation of the prior risk for respiratory infections by integrating transmission models with individual-level data from electronic medical records of 4.5 Million individuals, 2) identification of micro-changes in patients’ behaviour during the early phase of an infection by prospectively analysing digital sensory data from wearable devices and mobile phones of 5000 selected participants, 3) early detection of the causing pathogen validated with self-swab kits that are tested using RT-PCR. Our preliminary work that combined an analysis of EMR and transmission modelling led to a change in public health policy in Israel. The proposed study has the potential to open new research directions on the hidden side of infectious diseases and to initiate a new era of personalized medicine through dramatic changes in patient-doctor interaction.